Tags

Type your tag names separated by a space and hit enter

Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype.
Breast Cancer Res Treat. 2006 Jul; 98(1):91-8.BC

Abstract

Members of the syndecan and glypican families of cell surface heparan sulfate proteoglycans (HSPGs) are modulators of growth factor signaling and cell adhesion. Both loss and gain in expression of syndecans and glypicans has been associated with malignant progression. The goal of this project was to investigate a possible relationship between expression of cell surface HSPGs (syndecan-1, syndecan-4 and glypican-1) and established prognostic factors or clinical outcome in breast carcinomas. Tissue arrays containing 207 human breast carcinoma samples in duplicate were immuno-labeled with antibodies to syndecan-1, syndecan-4, glypican-1, Ki67, E-cadherin, estrogen receptor (ER) and progesterone receptor (PR). Clinical follow-up information was available for up to 18.6 years (median follow-up 6.2 years). Syndecan-1 and syndecan-4 expression in carcinoma cells ranged from complete loss to high expression, but glypican-1 was detected only in a small subset of breast carcinomas. Expression of all three HSPGs was significantly associated with the Ki67 proliferation index (syndecan-1: p=0.0025; syndecan-4: p<0.0001; glypican-1 p=0.01). Syndecan-1 and syndecan-4 expression correlated with ER negativity, grade, and size of the primary tumors. Syndecan-1 expression (but not syndecan-4 nor glypican-1) predicted patient outcome (DFS: p=0.0054; OS: p=0.0086). However, multivariate analysis failed to identify syndecan-1 as an independent prognostic marker, which was due to its significant association with established prognostic factors. The strong association between cell surface HSPGs and the Ki67 proliferation marker would support a biologic role in carcinoma growth regulation. Furthermore, the close correlation between syndecan expression and negative ER status raises the possibility of hormonal regulation or more likely an association with an aggressive, ER-negative carcinoma phenotype.

Authors+Show Affiliations

Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI 53792, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16636895

Citation

Baba, Füsun, et al. "Syndecan-1 and Syndecan-4 Are Overexpressed in an Estrogen Receptor-negative, Highly Proliferative Breast Carcinoma Subtype." Breast Cancer Research and Treatment, vol. 98, no. 1, 2006, pp. 91-8.
Baba F, Swartz K, van Buren R, et al. Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype. Breast Cancer Res Treat. 2006;98(1):91-8.
Baba, F., Swartz, K., van Buren, R., Eickhoff, J., Zhang, Y., Wolberg, W., & Friedl, A. (2006). Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype. Breast Cancer Research and Treatment, 98(1), 91-8.
Baba F, et al. Syndecan-1 and Syndecan-4 Are Overexpressed in an Estrogen Receptor-negative, Highly Proliferative Breast Carcinoma Subtype. Breast Cancer Res Treat. 2006;98(1):91-8. PubMed PMID: 16636895.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype. AU - Baba,Füsun, AU - Swartz,Kathryn, AU - van Buren,Regina, AU - Eickhoff,Jens, AU - Zhang,Yong, AU - Wolberg,William, AU - Friedl,Andreas, Y1 - 2006/04/25/ PY - 2005/11/29/received PY - 2005/12/05/accepted PY - 2006/4/26/pubmed PY - 2007/1/12/medline PY - 2006/4/26/entrez SP - 91 EP - 8 JF - Breast cancer research and treatment JO - Breast Cancer Res Treat VL - 98 IS - 1 N2 - Members of the syndecan and glypican families of cell surface heparan sulfate proteoglycans (HSPGs) are modulators of growth factor signaling and cell adhesion. Both loss and gain in expression of syndecans and glypicans has been associated with malignant progression. The goal of this project was to investigate a possible relationship between expression of cell surface HSPGs (syndecan-1, syndecan-4 and glypican-1) and established prognostic factors or clinical outcome in breast carcinomas. Tissue arrays containing 207 human breast carcinoma samples in duplicate were immuno-labeled with antibodies to syndecan-1, syndecan-4, glypican-1, Ki67, E-cadherin, estrogen receptor (ER) and progesterone receptor (PR). Clinical follow-up information was available for up to 18.6 years (median follow-up 6.2 years). Syndecan-1 and syndecan-4 expression in carcinoma cells ranged from complete loss to high expression, but glypican-1 was detected only in a small subset of breast carcinomas. Expression of all three HSPGs was significantly associated with the Ki67 proliferation index (syndecan-1: p=0.0025; syndecan-4: p<0.0001; glypican-1 p=0.01). Syndecan-1 and syndecan-4 expression correlated with ER negativity, grade, and size of the primary tumors. Syndecan-1 expression (but not syndecan-4 nor glypican-1) predicted patient outcome (DFS: p=0.0054; OS: p=0.0086). However, multivariate analysis failed to identify syndecan-1 as an independent prognostic marker, which was due to its significant association with established prognostic factors. The strong association between cell surface HSPGs and the Ki67 proliferation marker would support a biologic role in carcinoma growth regulation. Furthermore, the close correlation between syndecan expression and negative ER status raises the possibility of hormonal regulation or more likely an association with an aggressive, ER-negative carcinoma phenotype. SN - 0167-6806 UR - https://www.unboundmedicine.com/medline/citation/16636895/Syndecan_1_and_syndecan_4_are_overexpressed_in_an_estrogen_receptor_negative_highly_proliferative_breast_carcinoma_subtype_ L2 - https://doi.org/10.1007/s10549-005-9135-2 DB - PRIME DP - Unbound Medicine ER -